39 related articles for article (PubMed ID: 15299079)
1. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.
Kramer MG; Masner M; Casales E; Moreno M; Smerdou C; Chabalgoity JA
BMC Cancer; 2015 Sep; 15():620. PubMed ID: 26347489
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer.
Xia Y; Gupta GK; Castano AP; Mroz P; Avci P; Hamblin MR
J Biophotonics; 2014 Nov; 7(11-12):897-905. PubMed ID: 23922221
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model.
Kamensek U; Sersa G; Cemazar M
Mol Cancer; 2013 Nov; 12(1):136. PubMed ID: 24219565
[TBL] [Abstract][Full Text] [Related]
5. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth.
Kiewlich D; Zhang J; Gross C; Xia W; Larsen B; Cobb RR; Biroc S; Gu JM; Sato T; Light DR; Heitner T; Willuda J; Vogel D; Monteclaro F; Citkowicz A; Roffler SR; Zajchowski DA
Neoplasia; 2006 Jan; 8(1):18-30. PubMed ID: 16533422
[TBL] [Abstract][Full Text] [Related]
6. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.
Masuda Y; Mita S; Sakamoto K; Ishiko T; Ogawa M
Cancer Immunol Immunother; 1995 Dec; 41(6):325-30. PubMed ID: 8635189
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.
Zhao Q; Hu J; Mitra A; Cutrera J; Zhang W; Zhang Z; Yan J; Xia X; Mahadeo KM; Livingston JA; Gorlick R; Li S
J Immunother Cancer; 2019 Jun; 7(1):154. PubMed ID: 31208461
[TBL] [Abstract][Full Text] [Related]
8. Carbon nanotubes targeted to the tumor microenvironment inhibit metastasis in a preclinical model of melanoma.
García-Hevia L; Soltani R; González J; Chaloin O; Ménard-Moyon C; Bianco A; L Fanarraga M
Bioact Mater; 2024 Apr; 34():237-247. PubMed ID: 38223536
[TBL] [Abstract][Full Text] [Related]
9. Research and development of
Sun X; Xie Z; Lei X; Huang S; Tang G; Wang Z
RSC Med Chem; 2023 Jul; 14(7):1209-1226. PubMed ID: 37484562
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oh E; Choi IK; Hong J; Yun CO
Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
[TBL] [Abstract][Full Text] [Related]
11. New insights into IL-12-mediated tumor suppression.
Tugues S; Burkhard SH; Ohs I; Vrohlings M; Nussbaum K; Vom Berg J; Kulig P; Becher B
Cell Death Differ; 2015 Feb; 22(2):237-46. PubMed ID: 25190142
[TBL] [Abstract][Full Text] [Related]
12. The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation.
Martinez JO; Evangelopoulos M; Karun V; Shegog E; Wang JA; Boada C; Liu X; Ferrari M; Tasciotti E
Biomaterials; 2014 Dec; 35(37):9824-9832. PubMed ID: 25176066
[TBL] [Abstract][Full Text] [Related]
13. D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice.
Cichoń T; Smolarczyk R; Matuszczak S; Barczyk M; Jarosz M; Szala S
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):341-51. PubMed ID: 24487722
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 prevents colorectal cancer liver metastases in mice.
Shen F; Li JL; Cai WS; Zhu GH; Gu WL; Jia L; Xu B
Onco Targets Ther; 2013; 6():523-6. PubMed ID: 23696707
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
Chinnasamy D; Yu Z; Theoret MR; Zhao Y; Shrimali RK; Morgan RA; Feldman SA; Restifo NP; Rosenberg SA
J Clin Invest; 2010 Nov; 120(11):3953-68. PubMed ID: 20978347
[TBL] [Abstract][Full Text] [Related]
16. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.
Hu J; Chen LJ; Liu L; Chen X; Chen PL; Yang G; Hou WL; Tang MH; Zhang F; Wang XH; Zhao X; Wei YQ
Exp Mol Med; 2008 Dec; 40(6):617-28. PubMed ID: 19116447
[TBL] [Abstract][Full Text] [Related]
17. Chemomechanical mapping of ligand-receptor binding kinetics on cells.
Lee S; Mandic J; Van Vliet KJ
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9609-14. PubMed ID: 17535923
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Rakhmilevich AL; Hooper AT; Hicklin DJ; Sondel PM
Mol Cancer Ther; 2004 Aug; 3(8):969-76. PubMed ID: 15299079
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
